No mortality benefit to prostate cancer screening
Added: Monday 20 August 2012
New data shows that there is no evidence of a mortality benefit from being screened for prostate cancer. The Prostate, Lung, Colorectal and Ovarian (PLCO) randomised screening trial shows that men who had annual screening had no mortality benefit over the control group. Men in the annual screening group had a higher incidence of prostate cancer, suggesting that regular screening can lead to overdiagnosis.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: